A new start
Latuda treatment resulted in significant improvements in the PANSS total score and CGI-S score compared with placebo at Week 6.1,2
In two separate studies, Latuda began to significantly improve PANSS total scores compared with placebo from Day 41 and Week 1 respectively.2
Latuda may offer the efficacy you expect
In a post-hoc analysis, Latuda was not significantly different from olanzapine in demonstrating improvements on PANSS total score and CGI-S score at Week 6.2 Olanzapine was included for assay sensitivity.2
LS mean change from baseline in PANSS total score after 6 weeks of treatment2
p-values vs. placebo: *p<0.05; ***p<0.001.
Olanzapine was included for assay sensitivity.
Adapted from Meltzer HY et al. 20112
Consider long-term efficacy
Latuda was shown to be non-inferior to quetiapine XR in time-to-relapse over 12 months treatment.3
In a post-hoc analysis 12 months' treatment with Latuda was associated with a 56.7% relative risk reduction (13.3% absolute reduction) in the probability of hospitalisation vs. quetiapine XR (hazard ratio=0.433).3
Latuda delivered sustained improvements from baseline in PANSS total score and symptom improvement over 12 months.3
Probability of relapse over 12 months’ treatment.3
Hazard ratio: 0.728; 95% CI: 0.410–1.295; Log-rank p=0.28.
Adapted from Loebel A et al. 20133
CGI-S, Clinical Global Impressions Severity; CI, confidence interval; LS, least squares; PANSS, Positive and Negative Syndrome Scale.